Sherman Associates is set to build a $138.5M mixed-income housing project along Rochester’s riverfront, with 341 new units ...

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other top ...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US ...

The US photographer Cindy Sherman has launched a new initiative to preserve the physical and conceptual integrity of her work. The Cindy Sherman Legacy Project (CSLP), launching today (16 June ...

The Generator Blueprint is located in chapter 4 of Nikke’s story campaign, Bouquet. You’ll want to head to the very top corner of the map, and look for a jagged corner just to the left edge.

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 billion. Blueprint specializes in systemic mastocytosis and other ...

Completing VC Summer reactors would add carbon-free electricity to SC grid and prepare for rising power demand from ...

The Blueprint deal comes after Sanofi made an unsuccessful play in 2022 for another rare disease specialist, Horizon Therapeutics. In that case, Amgen took the prize with its $27.8 billion offer.

NYC Launches First-Ever City-Backed VC Internship Program to Expand Access for ... This inaugural effort represents more than a VC internship program; it’s a blueprint for building a more ...

Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, the companies said today, in a deal designed to expand the buyer’s rare immunological disease portfolio ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European ...